A Randomized, Double-Blind, Two-Period Crossover Study to Assess Safety, Tolerability, and Pharmacokinetics Following Repeated Doses of AZD6140 (400 mg od) and Digoxin (0.25 mg od) in Healthy Male and Female Volunteers
Study identifier:D5130C05265
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double-Blind, Two-Period Crossover Study to Assess Safety, Tolerability, and Pharmacokinetics Following Repeated Doses of AZD6140 (400 mg od) and Digoxin (0.25 mg od) in Healthy Male and Female Volunteers
Medical condition
pharmacokinetics
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Sept 2003
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
